Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

eyecare division

This page shows the latest eyecare division news and features for those working in and with pharma, biotech and healthcare.

Francis exits Sandoz, reigniting spinoff rumours

Francis exits Sandoz, reigniting spinoff rumours

Novartis says no such plans at present. Novartis’ struggling generics division Sandoz has lost its chief Richard Francis, who  announced he is unable to “commit to [Sandoz’s] multi-year journey”. ... Novartis already have the spin-off of its

Latest news

  • Novartis aims for 10 blockbuster launches by 2020 Novartis aims for 10 blockbuster launches by 2020

    The company also announced cuts to its manufacturing operations, and confirmed the spin off of eyecare division Alcon, which could raise as much as $35bn this year. ... The company has a new head of its oncology division, Susanne Schaffert, who took up

  • Alcon spin-out more likely but not imminent, says Novartis Alcon spin-out more likely but not imminent, says Novartis

    A stand-alone company could offer “additional shareholder value”. A better financial performance by Novartis’ eyecare division Alcon seems to be raising the chances of it being spun out of the ... and subsuming ophthalmic drugs into the pharma

  • Vas Narasimhan takes top Novartis job on Jimenez departure Vas Narasimhan takes top Novartis job on Jimenez departure

    The handover comes as Novartis is emerging from a difficult couple of years following the patent expiry for cancer blockbuster Glivec/Gleevec (imatinib), difficulties at its eyecare division Alcon - which recently

  • Alcon's return to growth gives Novartis 'options', says CEO Alcon's return to growth gives Novartis 'options', says CEO

    Sales up 3% to $1.5bn in second quarter for ailing eyecare division. ... The turnaround effort at Novartis' ailing eyecare division Alcon seems to be having an effect, with sales up 3% to $1.5bn in the second quarter after a long period of

  • New drugs can't keep Novartis sales on the up New drugs can't keep Novartis sales on the up

    Meanwhile, eyecare division Alcon - which is struggling to handle growing competition in the market and may be sold or spun off - posted another small (1%) decline in sales.

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest appointments

  • Alcon names president EMEA Alcon names president EMEA

    Riad Sherif joins from Novartis’ Canada business. Dr Riad Sherif has left his role at Novartis in Canada to join the pharma giant's eyecare business Alcon as president for the ... He now heads the EMEA region for Alcon, which is the global leader in

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
VISFO

A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....

Quick links